Suvannasankha, A., Bahlis, N. J., Trudel, S., Weisel, K., Koenecke, C., Oriol, A., . . . Nooka, A. (2024). Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Citação norma ChicagoSuvannasankha, Attaya, et al. Safety and Efficacy of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed or Refractory Multiple Myeloma. 2024.
Citação norma MLASuvannasankha, Attaya, et al. Safety and Efficacy of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed or Refractory Multiple Myeloma. 2024.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.